文献速递前列腺癌

帕博利珠单抗联合前列腺冷冻治疗新诊断寡转移激素敏感前列腺癌的初步试验

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-10-14

这项单中心初步试验纳入12例新诊断寡转移激素敏感前列腺癌患者,评估全前列腺冷冻消融联合短期雄激素剥夺(8个月)和帕博利珠单抗(6剂)的安全性与可行性。主要终点为1年时PSA<0.6 ng/mL的患者数和不良事件频率。中位无进展生存期14个月,中位无系统治疗生存期17.5个月;所有不良事件≤2级,冷冻治疗无明显并发症。结论认为方案耐受良好,但睾酮恢复后持续疾病控制少见。

要点

  • 全前列腺冷冻联合短期ADT和帕博利珠单抗耐受良好,不良事件≤2级。
  • 中位无进展生存期14个月,中位无系统治疗生存期17.5个月。

核心结论

  • 全前列腺冷冻消融联合短期雄激素剥夺和帕博利珠单抗在寡转移前列腺癌患者中耐受良好,未观察到安全性问题。
  • 尽管大多数患者局部病变得到有效治疗,但睾酮恢复后持续疾病控制不常见。

研究设计与样本

  • 单中心初步试验,2015至2016年招募12例新诊断寡转移前列腺癌患者。
  • 患者接受全前列腺冷冻消融联合短期雄激素剥夺(8个月)和帕博利珠单抗(6剂)。
  • 主要终点为1年时PSA<0.6 ng/mL的患者数和不良事件频率。

主要发现

  • 中位无进展生存期14个月,中位无系统治疗生存期17.5个月。
  • 可评估组织中PD-L1免疫组化未检出表达。
  • 所有不良事件≤2级,冷冻治疗无明显并发症。

临床怎么用

  • 该联合方案安全性可接受,但睾酮恢复后持续疾病控制少见,需谨慎评估适用人群。

局限性

  • 单中心初步试验,样本量小(12例),随访时间有限。
  • 探索性PD-L1分析仅限可评估组织,未报告具体例数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. METHODS: This single-institution, pilot trial recruited 12 patients with newly diagnosed oligometastatic prostate cancer between 2015 and 2016. Patients underwent whole-prostate cryoablation combined with short-term androgen deprivation (eight months) and pembrolizumab (6 doses). The primary clinical endpoints were the number of patients with a PSA level of <0.6 ng/mL at one year and the frequency of adverse events. Other outcome measures included progression-free survival and systemic therapy-free survival. Exploratory analyses included PD-L1 protein expression. RESULTS: Forty two percent (5/12) of patients had a PSAs of <0.6 ng/mL at one year though only 2 of these patients had recovered their testosterone at this time point. Median progression-free survival was 14 months, and median systemic therapy-free survival was 17.5 months. PD-L1 expression was not detectable by IHC in patients with evaluable tissue. All adverse events were grade ≤2, and there were no apparent complications from cryotherapy. CONCLUSIONS: Whole-prostate cryoablation combined with short-term androgen deprivation and pembrolizumab treatment was well tolerated and no safety concerns were observed in men with oligometastatic prostate cancer. Though local disease appeared effectively treated in the majority of men, the regimen only infrequency led to sustained disease control following testosterone recovery.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ross AE, Hurley PJ, Tran PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 31611635. doi:10.1038/s41391-019-0176-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。